annual CFO:
-$8.31M-$112.47M(-107.98%)Summary
- As of today (June 22, 2025), ALNY annual cash flow from operations is -$8.31 million, with the most recent change of -$112.47 million (-107.98%) on December 31, 2024.
- During the last 3 years, ALNY annual CFO has risen by +$633.38 million (+98.70%).
- ALNY annual CFO is now -104.23% below its all-time high of $196.52 million, reached on December 31, 2007.
Performance
ALNY Cash from operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFO:
-$118.31M-$23.65M(-24.99%)Summary
- As of today (June 22, 2025), ALNY quarterly cash flow from operations is -$118.31 million, with the most recent change of -$23.65 million (-24.99%) on March 31, 2025.
- Over the past year, ALNY quarterly CFO has dropped by -$36.80 million (-45.14%).
- ALNY quarterly CFO is now -132.92% below its all-time high of $359.41 million, reached on September 30, 2023.
Performance
ALNY quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFO:
-$45.11M-$36.80M(-442.72%)Summary
- As of today (June 22, 2025), ALNY TTM cash flow from operations is -$45.11 million, with the most recent change of -$36.80 million (-442.72%) on March 31, 2025.
- Over the past year, ALNY TTM CFO has dropped by -$234.23 million (-123.85%).
- ALNY TTM CFO is now -112.12% below its all-time high of $372.26 million, reached on June 30, 2024.
Performance
ALNY TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ALNY Cash from operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -108.0% | -45.1% | -123.8% |
| 3 y3 years | +98.7% | +30.9% | +92.2% |
| 5 y5 years | +97.0% | +51.9% | +86.6% |
ALNY Cash from operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -108.0% | +98.7% | -132.9% | +30.9% | -112.1% | +92.2% |
| 5 y | 5-year | -108.0% | +98.7% | -132.9% | +51.9% | -112.1% | +94.1% |
| alltime | all time | -104.2% | +98.7% | -132.9% | +51.9% | -112.1% | +94.1% |
ALNY Cash from operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$118.31M(+25.0%) | -$45.11M(+442.7%) |
| Dec 2024 | -$8.31M(-108.0%) | -$94.66M(-316.6%) | -$8.31M(-114.7%) |
| Sep 2024 | - | $43.71M(-64.8%) | $56.55M(-84.8%) |
| Jun 2024 | - | $124.16M(-252.3%) | $372.26M(+96.8%) |
| Mar 2024 | - | -$81.52M(+173.6%) | $189.12M(+81.6%) |
| Dec 2023 | $104.16M(-119.2%) | -$29.80M(-108.3%) | $104.16M(+5179.1%) |
| Sep 2023 | - | $359.41M(-709.3%) | $1.97M(-100.4%) |
| Jun 2023 | - | -$58.99M(-64.6%) | -$472.72M(-11.9%) |
| Mar 2023 | - | -$166.47M(+26.1%) | -$536.56M(-0.9%) |
| Dec 2022 | -$541.27M(-15.6%) | -$131.98M(+14.5%) | -$541.27M(-3.2%) |
| Sep 2022 | - | -$115.28M(-6.1%) | -$559.44M(-3.2%) |
| Jun 2022 | - | -$122.82M(-28.3%) | -$578.19M(+0.2%) |
| Mar 2022 | - | -$171.19M(+14.0%) | -$577.23M(-10.0%) |
| Dec 2021 | -$641.69M(+4.3%) | -$150.14M(+12.0%) | -$641.69M(+4.4%) |
| Sep 2021 | - | -$134.04M(+10.0%) | -$614.70M(+4.0%) |
| Jun 2021 | - | -$121.86M(-48.3%) | -$590.99M(-2.2%) |
| Mar 2021 | - | -$235.66M(+91.4%) | -$604.46M(-1.7%) |
| Dec 2020 | -$614.96M(+120.9%) | -$123.14M(+11.6%) | -$614.96M(-10.6%) |
| Sep 2020 | - | -$110.33M(-18.5%) | -$687.80M(-9.5%) |
| Jun 2020 | - | -$135.33M(-45.0%) | -$760.10M(+126.2%) |
| Mar 2020 | - | -$246.16M(+25.6%) | -$336.08M(+20.7%) |
| Dec 2019 | -$278.43M(-50.5%) | -$195.98M(+7.3%) | -$278.43M(+19.5%) |
| Sep 2019 | - | -$182.63M(-163.3%) | -$232.90M(+14.1%) |
| Jun 2019 | - | $288.69M(-253.1%) | -$204.08M(-65.7%) |
| Mar 2019 | - | -$188.51M(+25.3%) | -$595.46M(+5.8%) |
| Dec 2018 | -$562.62M(+47.0%) | -$150.46M(-2.2%) | -$562.62M(+9.2%) |
| Sep 2018 | - | -$153.81M(+49.8%) | -$515.20M(+12.1%) |
| Jun 2018 | - | -$102.69M(-34.0%) | -$459.76M(+4.9%) |
| Mar 2018 | - | -$155.66M(+51.1%) | -$438.12M(+14.5%) |
| Dec 2017 | -$382.79M(+24.4%) | -$103.04M(+4.8%) | -$382.79M(+6.9%) |
| Sep 2017 | - | -$98.36M(+21.4%) | -$358.08M(+6.8%) |
| Jun 2017 | - | -$81.05M(-19.2%) | -$335.25M(+3.3%) |
| Mar 2017 | - | -$100.33M(+28.1%) | -$324.41M(+5.4%) |
| Dec 2016 | -$307.70M(+62.7%) | -$78.34M(+3.7%) | -$307.70M(+8.9%) |
| Sep 2016 | - | -$75.54M(+7.6%) | -$282.43M(+8.1%) |
| Jun 2016 | - | -$70.20M(-16.0%) | -$261.26M(+6.0%) |
| Mar 2016 | - | -$83.62M(+57.6%) | -$246.51M(+30.3%) |
| Dec 2015 | -$189.14M(+14.2%) | -$53.06M(-2.4%) | -$189.14M(+9.5%) |
| Sep 2015 | - | -$54.37M(-2.0%) | -$172.71M(+8.6%) |
| Jun 2015 | - | -$55.46M(+111.2%) | -$159.05M(+5.9%) |
| Mar 2015 | - | -$26.25M(-28.3%) | -$150.22M(-9.3%) |
| Dec 2014 | -$165.64M | -$36.63M(-10.0%) | -$165.64M(+9.4%) |
| Sep 2014 | - | -$40.71M(-12.7%) | -$151.38M(+14.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2014 | - | -$46.63M(+11.9%) | -$132.38M(+21.1%) |
| Mar 2014 | - | -$41.67M(+86.3%) | -$109.36M(+59.3%) |
| Dec 2013 | -$68.66M(-40.6%) | -$22.37M(+3.0%) | -$68.66M(-40.4%) |
| Sep 2013 | - | -$21.71M(-8.0%) | -$115.20M(+30.5%) |
| Jun 2013 | - | -$23.60M(+2330.7%) | -$88.27M(+2.2%) |
| Mar 2013 | - | -$971.00K(-98.6%) | -$86.36M(-25.3%) |
| Dec 2012 | -$115.61M(+32.8%) | -$68.91M(-1422.2%) | -$115.61M(+60.9%) |
| Sep 2012 | - | $5.21M(-124.0%) | -$71.86M(-32.3%) |
| Jun 2012 | - | -$21.69M(-28.2%) | -$106.09M(-4.4%) |
| Mar 2012 | - | -$30.21M(+20.1%) | -$110.98M(+27.5%) |
| Dec 2011 | -$87.07M(+3.2%) | -$25.16M(-13.3%) | -$87.07M(+5.8%) |
| Sep 2011 | - | -$29.02M(+9.2%) | -$82.30M(+6.5%) |
| Jun 2011 | - | -$26.58M(+321.6%) | -$77.31M(+3.0%) |
| Mar 2011 | - | -$6.30M(-69.1%) | -$75.05M(-11.0%) |
| Dec 2010 | -$84.34M(+16.9%) | -$20.39M(-15.2%) | -$84.34M(+4.4%) |
| Sep 2010 | - | -$24.04M(-1.1%) | -$80.82M(+4.5%) |
| Jun 2010 | - | -$24.31M(+55.8%) | -$77.37M(-13.0%) |
| Mar 2010 | - | -$15.60M(-7.5%) | -$88.98M(+23.3%) |
| Dec 2009 | -$72.14M(-210.2%) | -$16.87M(-18.1%) | -$72.14M(+20.0%) |
| Sep 2009 | - | -$20.59M(-42.7%) | -$60.13M(+8.2%) |
| Jun 2009 | - | -$35.92M(-3017.9%) | -$55.55M(-173.7%) |
| Mar 2009 | - | $1.23M(-125.4%) | $75.38M(+15.1%) |
| Dec 2008 | $65.49M(-66.7%) | -$4.85M(-69.7%) | $65.49M(+5.8%) |
| Sep 2008 | - | -$16.01M(-116.9%) | $61.90M(-79.5%) |
| Jun 2008 | - | $95.01M(-1197.3%) | $302.22M(+52.0%) |
| Mar 2008 | - | -$8.66M(+2.6%) | $198.82M(+1.2%) |
| Dec 2007 | $196.52M(-897.9%) | -$8.44M(-103.8%) | $196.52M(-1.9%) |
| Sep 2007 | - | $224.31M(-2773.2%) | $200.34M(-844.9%) |
| Jun 2007 | - | -$8.39M(-23.4%) | -$26.90M(+0.0%) |
| Mar 2007 | - | -$10.96M(+137.6%) | -$26.89M(+9.2%) |
| Dec 2006 | -$24.63M(+49.4%) | -$4.61M(+57.3%) | -$24.63M(+50.2%) |
| Sep 2006 | - | -$2.93M(-65.0%) | -$16.40M(-16.7%) |
| Jun 2006 | - | -$8.38M(-3.7%) | -$19.68M(+12.1%) |
| Mar 2006 | - | -$8.70M(-340.7%) | -$17.55M(+6.5%) |
| Dec 2005 | -$16.48M(-15.8%) | $3.62M(-158.2%) | -$16.48M(-21.9%) |
| Sep 2005 | - | -$6.21M(-0.6%) | -$21.12M(+14.0%) |
| Jun 2005 | - | -$6.25M(-18.2%) | -$18.52M(-1.1%) |
| Mar 2005 | - | -$7.64M(+651.9%) | -$18.71M(-4.4%) |
| Dec 2004 | -$19.57M(+52.6%) | -$1.02M(-71.9%) | -$19.57M(+5.5%) |
| Sep 2004 | - | -$3.61M(-44.0%) | -$18.55M(+24.2%) |
| Jun 2004 | - | -$6.45M(-24.1%) | -$14.94M(+75.9%) |
| Mar 2004 | - | -$8.49M | -$8.49M |
| Dec 2003 | -$12.83M(+903.8%) | - | - |
| Dec 2002 | -$1.28M | - | - |
FAQ
- What is Alnylam Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual CFO year-on-year change?
- What is Alnylam Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly CFO year-on-year change?
- What is Alnylam Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals TTM CFO year-on-year change?
What is Alnylam Pharmaceuticals annual cash flow from operations?
The current annual CFO of ALNY is -$8.31M
What is the all time high annual CFO for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual cash flow from operations is $196.52M
What is Alnylam Pharmaceuticals annual CFO year-on-year change?
Over the past year, ALNY annual cash flow from operations has changed by -$112.47M (-107.98%)
What is Alnylam Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of ALNY is -$118.31M
What is the all time high quarterly CFO for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly cash flow from operations is $359.41M
What is Alnylam Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, ALNY quarterly cash flow from operations has changed by -$36.80M (-45.14%)
What is Alnylam Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of ALNY is -$45.11M
What is the all time high TTM CFO for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high TTM cash flow from operations is $372.26M
What is Alnylam Pharmaceuticals TTM CFO year-on-year change?
Over the past year, ALNY TTM cash flow from operations has changed by -$234.23M (-123.85%)